Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers

5 Nov 2020

Abstract excerpt

A first-in-human phase I trial of Vvax001, an alphavirus-based therapeutic cancer vaccine against human papillomavirus (HPV)-induced cancers was performed assessing immunological activity, safety, and tolerability. Vvax001 consists of replication-incompetent Semliki Forest virus replicon particles encoding HPV16-derived antigens E6 and E7. Twelve participants with a history of cervical intraepithelial neoplasia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to Hepatitis B Virus Studies
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33160073
DOI: 10.1016/j.ymthe.2020.11.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced CancersPMID 33160073Read ↗

Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancerSemantic proximity Read ↗

Self-replicating alphavirus RNA vaccinesSemantic proximity Read ↗

Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1Semantic proximity Read ↗

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirusSemantic proximity Read ↗

A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins.Semantic proximity Read ↗

Alphavirus replicon vaccinesSemantic proximity Read ↗

Replicon RNA Viral Vectors as VaccinesSemantic proximity Read ↗

NSP4 as Adjuvant for Immunogenicity and Design of Effective Therapeutic HPV16 E6/E7/L1 DNA Vaccine in Tumoric and Healthy C57BL/6 MiceSemantic proximity Read ↗

Immunotherapy Against HPV16/18 Generates Potent T <sub>H</sub> 1 and Cytotoxic Cellular Immune ResponsesSemantic proximity Read ↗

Alphavirus-based Vaccines Encoding Nonstructural Proteins of Hepatitis C Virus Induce Robust and Protective T-cell ResponsesSemantic proximity Read ↗

An Alphavirus Replicon Particle Chimera Derived from Venezuelan Equine Encephalitis and Sindbis Viruses Is a Potent Gene-Based Vaccine Delivery VectorSemantic proximity Read ↗

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.